02.20.18
ChromaDex Corporation, an integrated, science-based, nutraceutical company devoted to improving the way people age, has registered two new collaborative human clinical studies on NIAGEN Nicotinamide Riboside (NR), and studies are underway at the University of Cambridge and the University of Washington.
ChromaDex Co-Founder and CEO, Frank Jaksch, commented, “With nearly 140 collaborative agreements in place, we continue to shape the landscape of NR and NAD research, ensuring that each study helps to quantify the value of NIAGEN and its role in human health.”
The University of Cambridge research team will study 15 patients with mitochondrial disease to determine whether NIAGEN induces mitochondrial biogenesis and affects mitochondrial function in patients with mitochondrial myopathy. This trial is expected to complete in late Spring, 2019.
The second study, at the University of Washington, will include 30 patients with clinically stable, systolic heart failure. The research team primarily aims to assess the safety and tolerability of NIAGEN in this high-risk population. The team will also collect exploratory data on the effects of NIAGEN on cardiovascular functional capacity in these patients. Registration of the study quickly follows publication of their last human clinical trial which published early December, 2017. This latest study is currently expected to complete at the end of June, 2018.
“By offering clinical study products at no cost for double-blind, placebo controlled independent research, we are enabling the next phase of research in humans, and in at-risk populations where NIAGEN has the potential to improve quality of life. Most of these major human investigations are funded by national research funding bodies and other research organizations unrelated to ChromaDex which attests to the promising future of NIAGEN,” Robert N. Fried, president and chief operating officer of ChromaDex shared.
ChromaDex has enabled global NIAGEN research in a diverse set of health-related fields by providing their safety-verified, NIAGEN at no cost to independent investigators who are leading nearly 140 programs in 34 different areas of health research including brain health, Alzheimer’s and cognitive support, heart health, and inflammation. To date there are 3 published clinical trials of NIAGEN and NIAGEN is being studied in at least 13 of the 16 human trials currently registered on clinicaltrials.gov.
ChromaDex Co-Founder and CEO, Frank Jaksch, commented, “With nearly 140 collaborative agreements in place, we continue to shape the landscape of NR and NAD research, ensuring that each study helps to quantify the value of NIAGEN and its role in human health.”
The University of Cambridge research team will study 15 patients with mitochondrial disease to determine whether NIAGEN induces mitochondrial biogenesis and affects mitochondrial function in patients with mitochondrial myopathy. This trial is expected to complete in late Spring, 2019.
The second study, at the University of Washington, will include 30 patients with clinically stable, systolic heart failure. The research team primarily aims to assess the safety and tolerability of NIAGEN in this high-risk population. The team will also collect exploratory data on the effects of NIAGEN on cardiovascular functional capacity in these patients. Registration of the study quickly follows publication of their last human clinical trial which published early December, 2017. This latest study is currently expected to complete at the end of June, 2018.
“By offering clinical study products at no cost for double-blind, placebo controlled independent research, we are enabling the next phase of research in humans, and in at-risk populations where NIAGEN has the potential to improve quality of life. Most of these major human investigations are funded by national research funding bodies and other research organizations unrelated to ChromaDex which attests to the promising future of NIAGEN,” Robert N. Fried, president and chief operating officer of ChromaDex shared.
ChromaDex has enabled global NIAGEN research in a diverse set of health-related fields by providing their safety-verified, NIAGEN at no cost to independent investigators who are leading nearly 140 programs in 34 different areas of health research including brain health, Alzheimer’s and cognitive support, heart health, and inflammation. To date there are 3 published clinical trials of NIAGEN and NIAGEN is being studied in at least 13 of the 16 human trials currently registered on clinicaltrials.gov.
